Chih-wei Yen

Jiayi Shi, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Journal: PloS one

Published: May 28, 2022

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.

Journal: BMC gastroenterology

Published: April 19, 2021

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.

Journal: Journal of gastroenterology and hepatology

Published: March 09, 2021

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: February 11, 2021

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.

Journal: Scientific reports

Published: September 20, 2020

High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.

High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: April 24, 2020

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.

Journal: PloS one

Published: January 03, 2020

Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin.

Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 09, 2019

Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.

Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.

Journal: Scientific reports

Published: July 27, 2018

Hepatocellular carcinoma with thoracic metastases presenting as hemothorax: A case report and literature review.

Hepatocellular carcinoma with thoracic metastases presenting as hemothorax: A case report and literature review.

Journal: Medicine

Published: June 01, 2018

Adult renal neuroblastoma: A case report and literature review.

Adult renal neuroblastoma: A case report and literature review.

Journal: Medicine

Published: April 06, 2018

Did AFP-L3 save ultrasonography in community screening?

Did AFP-L3 save ultrasonography in community screening?

Journal: The Kaohsiung journal of medical sciences

Published: February 27, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026